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Abstract
Background: Five-fluorouracil (FU), mainly associated with leucovorin (L), plays an essential role
in chemotherapy of colorectal carcinoma. Moreover, FU ± L has been found to increase the
expression of tumor-associated carcinoembryonic antigen (CEA), that may be an important target
in therapeutic protocols of active specific immunotherapy. FU + L (FUL) are frequently combined
with oxaliplatin (OXA) in advanced colon cancer patients. Thus, we investigated whether FUL in
combination with OXA according to 2 different schedules may influence CEA expression in human
colon cancer cells in vitro.
Methods: CEA protein expression was evaluated by cytofluorimetric and western blot analysis.
Relative quantification of CEA mRNA was assessed by real time RT-PCR analysis.
Results: Levels of CEA protein and transcript were found to be higher in FUL-treated cells than
in controls. However, when target cells were exposed to OXA before but not after FUL treatment,
the up-regulation of CEA was partially inhibited.
Conclusion: These results suggest that target cells must be exposed to OXA after but not before
treatment with the fluoropyrimidine in order to exploit drug-induced up-regulation of CEA. This
finding appears to provide useful information to design chemo-immunotherapy protocols based on
FUL + OXA, combined with host's immunity against CEA directed cancer vaccines.
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Background
Colorectal cancer is one of the most commonly occurring
malignancies in the world, and the prognosis for patients
with advanced colorectal cancer with distant metastasis
may be very poor. Among the antitumor agents, 5-fluor-
ouracil (FU) is considered the reference drug for the treat-
ment of advanced colon cancer. It is considered equally
active in the treatment of a number of other common
malignancies such breast, gastric and head and neck can-
cer [1].
In the last 5 years, FU was more frequently used in combi-
nation with other agents endowed with different mecha-
nism of action such as oxaliplatin (OXA) or irinotecan [2-
4] with which the antimetabolite has shown significant
synergistic interaction. FU has also been associated with
biotherapy, e.g. with monoclonal antibodies directed
against vascular endothelial growth factor, such as Bevaci-
zumab [5], or to the epidermal growth factor receptor,
such as Cetuximab [6]. In advanced colorectal cancer,
combination therapy appeared to provide better results in
terms of response rate and survival, respect to treatment
with FU alone [1-8]. These clinical trials, however, did not
show a noticeable cure rate or long term survival, and
there is a need for the development of new treatment
modalities, possibly involving specific immunotherapy.
Therefore, vaccine approaches has been proposed in order
to obtain eradication of target malignant cells. Actually, a
large variety of tumor-associated antigens (TAAs) has
been identified, allowing the development of several
tumor vaccines that are currently under investigation [9].
Carcinoembryonic antigen (CEA) is a 180,000 – 200,000
Mr glycoprotein, widely used as a human tumor marker.
CEA is present in various types of neoplasm, including
gastrointestinal, breast and lung carcinoma [10]. Since
this protein is scarcely expressed in normal tissues,
whereas moderate/high CEA levels are often present in
malignant cells, this tumor marker is considered a self
TAA and a target for immunotherapy [11,12]. A number
of clinical studies established that different strategies of
immunization, including recombinant viruses, DNA or
antiidiotypic antibodies can generate a CEA-specific cyto-
toxic T lymphocyte (CTL) response with anti-tumor activ-
ity in cancer patients and in mice [13-15].
An in vitro human CTL-mediated response to CEA has
been demonstrated using CEA-derived immunogenic
peptides (CEA-DIP) endowed with HLA-A(*)02.01 bind-
ing anchor motifs. One of these peptides (i.e. CAP-1) was
found to elicit CTL responses in HLA-compatible human
peripheral mononuclear cells (PBMC), obtained from
normal donors or from patients with colorectal carcinoma
[16].
Clinical trials are currently evaluating the possibility of
using CEA as target antigen in protocols of active specific
immunotherapy of patients with colorectal carcinoma. So
far, the preliminary results of these investigations did not
show the expected satisfactory results. It is possible that a
sufficiently large fraction of the entire tumor cell popula-
tion would not express adequate amounts of CEA-DIP to
be recognized by specific CTLs. Therefore, agents capable
of increasing the expression of CEA might represent suita-
ble tools to improve the efficacy of therapeutic
approaches, based on this tumor marker.
Our laboratory and other research groups have already
demonstrated that the level of CEA can be increased by a
number of therapeutic agents, including antitumor com-
pounds (drug-induced antigen remodeling, DIAR) [17].
In addition, FU treatment was found to enhance cancer
cell susceptibility to CEA specific CTL lines, generated
from human HLA-A (*)02.01-positive PBMC stimulated
in vitro with autologus dentritic cells pulsed with CEA-
DIP [18].
Recently, immune adjuvant regimen with interleukin-2
and granulocytes macrophage colony stimulating factor
has been tested in colon cancer patients in combination
with a FU-based chemotherapy regimen, termed "GOLF"
(i.e. gemcitabine; OXA; L and FU). The results of this
study have been encouraging, since this immuno-chemo-
therapy protocol showed a powerful anti-tumor activity in
metastatic colon cancer patients along with detectable
increase of circulating tumor-specific CTL precursors [19].
These results prompted us to investigate the influence of
OXA and FU, alone or in combination on CEA expression
in "in vitro" model of human colon cancer cells.
Methods
Cell cultures
Human colon cancer cell line HT-29 was obtained from
American Type Culture Collection (Rockville, MD).
Tumor cells were routinely grown in Dulbecco's Modified
Eagle Medium (DMEM), supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 10%, heat-inactivated, FCS (hyclone), hereafter called
"Complete Medium" (CM). At each line passage, cells
were removed using trypsin-EDTA solution [0.05%
trypsin and 0.02% ethylenediaminetetra-acetic acid
(EDTA) in phosphate buffered saline (PBS) without cal-
cium and magnesium].
Tumor cell treatment
Sub-confluent cells were removed by treatment with
trypsin, counted and 5 × 106 cells were seeded in T75
flasks in the final volume of 15 ml of CM (day 0) and
incubated at 37°C in an atmosphere of 5% CO2 and 90%Journal of Experimental & Clinical Cancer Research 2008, 27:5 http://www.jeccr.com/content/27/1/5
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humidity for 24 h. Thereafter, tumor cells were exposed to
FU (10-5M) + L (10-4 M) (i.e. FUL), or to OXA (10-4 M)
alone, or to FUL + OXA. This was done since preliminary
studies on the interaction between FU and OXA, showed
that the platinum compound was able to reduce the effect
of the fluoropyrimidine on CEA expression when tumor
cells were exposed to the 2 agents at the same time. In this
study, all treated groups were exposed to FUL for 2 days
(i.e. day 1 and 2), alone or combined with OXA, accord-
ing to 2 different schedules: (a) cell cultures were incu-
bated with OXA for 4 h in the morning of day 1, washed
and treated with FUL (i.e. OXA on day 1), or (b) OXA was
added to cell cultures on the morning of day 2, left for 4 h
and subjected to multiple washing. Thereafter, cultured
cells were re-exposed to FUL at the same concentration
until day 3. On day 3 the cells were detached by using
trypsin/EDTA, washed three times with PBS, counted and
tested for CEA.
PolyA (+) RNA isolation and Real-Time RT-PCR
PolyA(+)RNA was isolated using a Dynabeads direct
micro-kit (Dynal, Oslo, Norway). mRNA was eluted in 10
mM Tris-HCl (10 μl) after incubation of the Dynabeads-
mRNA complex at 92°C for 2 min. cDNA was synthesized
using 10 μl of eluted mRNA and TaqMan RT kit (Applied
Biosystems, Foster City, CA), according to the manufac-
turer's instructions. Real-time RT-PCR was performed in
triplicate using the ABI PRISM 7700 Sequence Detection
System (Perkin-Elmer, Wellesley, MA), according to the
manufacturer's instructions. The two primers (forward, 5'-
AGGACCACAGTCACGACGATC-3'; reverse, 5'-CTGGT-
GATGAAGGGTTTGGG-3') and the TaqMan probe (5'-
CAGTCTATGCAGAGCCA-3') were specifically designed
for the CEA gene using Primer Express v1.5a (Applied Bio-
systems). cDNA were amplified using PCR Master Mix
according to the following PCR conditions: 50°C for 2
min, 95°C for 10 min, followed by 40 cycles at 95°C for
15 s and 60°C for 1 min. To correct for the variation of
CEA mRNA value, real time RT-PCR analysis of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was carried
out using the TaqMan GAPDH control reagents kit
(Applied Biosystems).
Relative Quantification Method
The relative quantification of CEA was performed using
the comparative threshold cycle (CT) method (as
described by "Applied Biosystems") that uses an arithme-
tic formula (2-ΔΔCT), which requires equal PCRs efficiency.
ΔCT is the difference in the CT values between the target
carcinoembryonic antigen (average CT used, as each sam-
ple was analyzed in triplicate) and the endogenous con-
trol GAPDH. ΔΔCT is the difference between ΔCT of a
sample and the ΔCT of a calibrator sample. The mRNA
obtained from HT-29 cells was chosen as calibrator sam-
ple.
Cell extraction and electrophoresis
Cells were washed with PBS. The cell pellet was suspended
in 3 volumes of extraction buffer [(50 mM Tris-HCl, pH
7.5-1 mM Phenylmethylsulfonyl Fluoride – 2 mM ethyl-
ene glycol-bis(beta-amino-ethyl ether)-N, N, N', N'-tetra-
acetic acid – 400 mg/ml soybean trypsin inhibitor – 10
mM dithiothreitol – 5 μg/ml of aprotinin – 200 μg/ml of
leupeptin – 1% Triton X-100], kept on ice for 10 min, son-
icated for 5 sec and centrifuged for 5 min at 15,000 × g at
4°C in an Eppendorf microcentrifuge. Protein concentra-
tions were determined with the Bio Rad protein reagent
with bovine serum albumin as the standard. Proteins were
heated in a boiling water bath for 2 min, and separated in
10% sodium dodecyl sulfate (SDS) (w/v) polyacrylamide
gels using a mini-protean electrophoresis apparatus (Bio-
Rad, Hercules, CA, USA). All reagents were obtained from
Sigma.
Immunoblotting
The BioRad mini Trans-blot apparatus for electrophoresis
was used for electrotransfer of proteins to nitrocellulose
filters. The transfer was carried out at 25 V overnight. After
the transfer, membranes were incubated with 3% of non-
fat dry milk (Bio-Rad) in Tris buffered saline (TBS) (20
mM Tris-HCl pH 7.5, 0.9% NaCl) with gentle agitation,
for 30 min. The membranes were then incubated at room
temperature for 30 min, with COL-1 mAb (kindly pro-
vided by J.W. Greiner, National Cancer Institutes,
National Institutes of Health, Bethesda USA) diluted (14
μg/ml) in TBS containing 0.05% Tween 20 (TBST),
washed twice with TBST and incubated with alkaline
phosphatase-coupled secondary antibody diluted 1:7,500
in TBST for 30 min. The bands were visualized using the
Protoblot (Promega Biotec, Madison, WI, USA) color
development system, as described by the manufacturer.
Flow cytometry
Cancer cells were harvested with trypsin-EDTA solution,
washed twice with PBS containing 0.02% sodium azide
(Sigma) and distributed into 3-ml tubes (106 cell/tube).
The cells were incubated with an excess of the primary
anti-CEA monoclonal antibody (mAb) COL-1 in ice bath
for 30 min, followed by two washes in PBS containing
sodium azide. The cells were again incubated in ice bath
for 30 min, washed twice with cold PBS and analyzed
using a FACScan instrument (Becton-Dickinson, Ruther-
ford, NJ) equipped with a blue laser with an excitation of
level of 15 nW at 488 nm and the Lysis II program. Per-
centage of fluorescence of 10.000 cells was recorded and
the background control of individual samples was sub-
tracted. Data collections were gated utilizing forward light
scatter and side light scatter to exclude the minimal of cell
debris and aggregates. Data analysis was performed by
using "Consort 32" software on a Hewlett Packard com-
puter.Journal of Experimental & Clinical Cancer Research 2008, 27:5 http://www.jeccr.com/content/27/1/5
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Results
Influence of OXA treatment before or after exposure to 
FUL on the growth and CEA expression of HT-29 cells
Preliminary experiments suggested possible negative
interactions between FU and OXA on CEA expression,
when tumor cells were exposed to the 2 agents together.
Therefore, we decided to investigate the effect of FUL,
alone or combined with OXA on HT-29 colon cancer cells,
using different schedules of the two drugs, i.e. OXA given
before FUL (OXA day 1) or OXA given after 1-day expo-
sure to FUL (OXA day 2). This time schedule was adopted
in order to explore whether 1 day separation between FUL
and OXA treatment could be adequate to prevent negative
drug interaction on tumor marker expression. On day 3,
the number of viable cells (i.e., cells excluding trypan
blue) was counted and subjected to western blot (Figure
1) and FACS analysis.
Densitometric analysis of immunoblot (Figure 1B) indi-
cated that CEA levels were 4.7 fold higher in HT-29 cells
treated with FUL, in comparison to untreated controls.
Treatment with OXA alone, on day 1 or day 2, induced a
2.7 or 2.0-fold increase, respectively, of CEA expression
compared with untreated cells. However, when the cells
were exposed to OXA on day 1, before FU treatment, the
up-regulation of CEA was inhibited (Figure 1A, B). On the
contrary, when HT-29 cells were treated with OXA on day
2 (i.e. 1 day after exposure to FUL), the platinum com-
pound did not reduce sensibly the FUL-mediated up-reg-
ulation of CEA expression, which remained on the value
of approximately 4-fold increase. Western blot analysis
evaluated the total CEA content. Therefore, the expression
of CEA on the cell membrane was determined by using
FACS analysis. The results of a typical experiment illus-
trated in the legend of figure 2, indicate that the up-regu-
lation of membrane-associated CEA was partially
inhibited when the cells were exposed to OXA before,
instead of after FUL treatment.
The results, illustrated in figure 2 showed that treatment
with FUL is followed by 78% reduction of the total
number of cells. The sequential treatment of OXA before
FUL exhibited 83% of cell inhibition. No differences in
the growth rate were detected by using the reverse
sequence of drug combination (i.e. FUL before OXA).
Effect of FUL and OXA alone or in combination on CEA 
transcripts
Parallel experiments were performed in order to test
whether the increase of CEA protein resulting from drug
treatment of HT-29 cells with FUL and OXA alone or in
combination, could have also resulted in an increase of
CEA mRNA. Detection of CEA transcripts was carried out
by real time RT-PCR using the CEA specific probe and
primers, as described in "Materials and Methods". The
efficiency of amplification of CEA and GAPDH were
found to be equal. This enabled relative quantification of
CEA to be performed using the ΔΔCT comparative method
illustrated in the section of "Material and Methods"
The results described in Figure 3, showed that CEA tran-
scripts were 2.9 times higher in HT-29 cells treated with
FUL compared with those of untreated cells. Noteworthy,
CEA mRNA was found in a 3.1-fold greater abundance in
cells treated with FUL followed by OXA on day 2 in com-
Western blot (A) and densitometric analysis (B) of CEA  expression in HT-29 cells Figure 1
Western blot (A) and densitometric analysis (B) of 
CEA expression in HT-29 cells. Following treatment 
with oxaliplatin (OXA) before or after exposure to 5-fluor-
ouracil + leucovorin (FUL), cells were washed in PBS and the 
pellet was suspended in extraction buffer. Cell lysates were 
subjected to SDS-PAGE and immunoblotting was performed 
with MAb COL-1 for CEA detection. Molecular weights in 
kDa are placed on the left. See "material and methods" for 
experimental details. Immunoblot was scanned by densitom-
eter and the optical density was expressed as arbitrary units. 
OXA2, cells were treated with OXA on day 2; FUL-OXA2, 
FUL followed by OXA2 treatment; OXA1, cells were 
treated with OXA on day 1; OXA1-FUL, OXA1 followed by 
FUL treatment.Journal of Experimental & Clinical Cancer Research 2008, 27:5 http://www.jeccr.com/content/27/1/5
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parison to those in untreated cells. On the contrary it was
revealed only a 1.7 fold increase in the level of CEA when
the cells were exposed to OXA on day 1 before FUL treat-
ment.
Discussion
The results of the present study revealed a complex inter-
action between FUL and OXA, a triad of agents largely
used in colorectal cancer, on CEA expression of human
HT-29 colon cancer cells in vitro. From one side, our find-
ings confirm previous observations on the increase of CEA
expression by FUL, either at protein and transcript levels
[20]. On the other side, the data illustrated in this report,
showed a marginal increase of CEA expression in target
cells treated with OXA alone, respect to that detectable in
untreated controls. In contrast, exposure of cancer cells to
OXA prior to FUL treatment, antagonized consistently
FUL-induced up-regulation of the antigen. However, this
negative interaction did not appear to take place when tar-
get cells were exposed to the platinum derivative 24 h after
treatment with the fluoropyrimidine. Worth of note is the
observation that the short-term cytotoxic effects of drug
combination were essentially unaffected by the order of
OXA – FUL sequence. Moreover previous investigations
showed that FU and L treatment acted in synergy to
inhibit the growth of tumor cells in vitro but did not alter
CEA modulation induced by the antimetabolite [20]. All
these observations support greatly the hypothesis that
drug influence on CEA expression is not correlated with
tumor suppressive effects of these agents.
No data are presently available on the molecular bases
involved in the interaction between FU, L and OXA on the
expression of CEA.
It reasonable to hypothesize that the increase of CEA
mRNA observed after FUL treatment (see Figure 3) is
Relative CEA mRNA values of cells treated with 5-Fluorour- acil+leucovorin (FUL) and/or Oxaliplatin (OXA) Figure 3
Relative CEA mRNA values of cells treated with 5-
Fluorouracil+leucovorin (FUL) and/or Oxaliplatin 
(OXA). Details of cell treatment are illustrated in "Materials 
and Methods". The relative CEA mRNA values were meas-
ured by Real time RT-PCR and calculated using the compara-
tive CT method as described in "Materials and Methods". 
OXA2, cells were treated with OXA on day 2; FUL-OXA2, 
FUL followed by OXA2 treatment; OXA1, cells were 
treated with OXA on day 1; OXA1-FUL, OXA1 followed by 
FUL treatment.
Effects of oxaliplatin (OXA) and 5-fluorouracil+leucovorin  (FUL) on the HT-29 cells Figure 2
Effects of oxaliplatin (OXA) and 5-fluorouracil+leu-
covorin (FUL) on the HT-29 cells. Cells were treated 
with OXA on day 1 before exposure to FUL or on day 2 
after 24 h exposure to FUL. Treatment conditions are 
described in "Material and Methods". On day 3, cells were 
counted by trypan blue exclusion and CEA expression was 
measured by FACS analysis by using COL-1 mAb. Columns, 
total number of cells. Bars, SE of triplicate determinations. 
No significant difference was observed between the effects of 
FUL-OXA2 versus OXA1-FUL (p > 0.05). The percentage of 
the CEA-positive cells was as followed: 14.9 (untreated con-
trol); 30.1(FUL); 19.9 (OXA2); 26.2 (FUL-OXA2); 19.1 
(OXA1); 21.4 (OXA1-FUL). OXA2, cells were treated with 
OXA on day 2; FUL-OXA2, FUL followed by OXA2 treat-
ment; OXA1, cells were treated with OXA on day 1; OXA1-
FUL, OXA1 followed by FUL treatment.Journal of Experimental & Clinical Cancer Research 2008, 27:5 http://www.jeccr.com/content/27/1/5
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responsible, at least in part, of the enhanced CEA protein
levels as shown by the results of Figure 1. This is further
supported by previous findings demonstrating that treat-
ment with Actinomycin D, an inhibitor of RNA synthesis,
blocked the enhancement of CEA transcript in FU-treated
cells [18]. However, the actual biochemical mechanism
underlying FU-mediated increase of CEA is entirely
unknown. In any case, the hypothesis that selection of
CEA positive FU-resistant cells could play a role, does not
appear to be easily acceptable. In fact, FU-induced
increase of CEA levels was obtained also in C22.20 cell
line derived by sub-cloning a clone of HT-29 cells [21],
thus indicating that CEA up-regulation is based on bio-
chemical induction rather than selection.
The role possibly played by drug-induced up-regulation of
CEA expression deserves particular attention. Actually, it
has been demonstrated that immunogenic peptides, gen-
erated by endocellular processing of proteins predomi-
nantly located in malignant cells, can be presented in
association with HLA molecules to responder host's lym-
phocytes. In the present model, CEA-DIP has been shown
to elicit efficient cell mediated immunity, with generation
of HLA-restricted CTL [13,16]. Moreover, animal studies
demonstrated synergistic effects between antitumor
chemotherapy and immune responses, even when host's
responses are particularly weak [22]. Since drug-induced
up-regulation of CEA is followed by consistent increase of
CEA-DIP [18], this phenomenon could be exploited for
chemo-immunotherapy of CEA-positive neoplastic dis-
eases. Many CEA-based cancer vaccines approaches are
currently being evaluated in clinical trials involving
patients with malignant diseases of the digestive tract. The
preliminary results have shown that it is possible to
induce an effective antigen-specific cellular and humoral
response [9,13,14,16]. However, so far, no correlation has
been demonstrated between immunostimulation and
clinical outcome. One of the possible explanations is that
CEA is heterogeneously expressed in the tumor. Therefore,
some of the neoplastic cells may escape recognition by
vaccine-induced CEA-specific CTLs because of reduced
expression of target antigen. In the light of this hypothe-
sis, pharmacological intervention able to induce changes
of the antigenic-immunogenic profile of tumor cells is of
potential clinical interest. We and other authors previ-
ously reported that treatment with different compounds
(e.g. with fluoropyrimidine, staurosporine, interleukin-6
and interferons) may induce CEA up-regulation [17,23]. A
similar event has also been observed for the expression of
class-I HLA molecules [20]. Moreover, CEA expression
enhancing agents are able to increase the level of this anti-
gen in various clones expressing different basal level of the
marker, including clones expressing only marginal
amounts of CEA protein [24].
In conclusion, the rationale to utilize the optimal treat-
ment schedule of the FUL-OXA combination capable of
inducing both growth inhibition and CEA up-regulation,
appears to be of considerable value, since drug-induced
overexpression of the antigen is expected to make tumor
cells more susceptible to the cytolytic activity of specific
effector lymphocytes.
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